Paper455325
Experimental evaluation of anthracycline analogs.
Casazza AM. Cancer Treat Rep, 1979. Cited by 196 papers, by iCite.
Cite this record
ConductScience Library. Experimental evaluation of anthracycline analogs. Papers, record 455325. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/455325
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Naphthacenes | Major topic |
| Neoplasms, Experimental | Major topic |
| Animals | |
| Daunorubicin | |
| Disease Models, Animal | |
| Doxorubicin | |
| Drug Administration Schedule | |
| Drug Evaluation, Preclinical | |
| Glycosides | |
| HeLa Cells | |
| Heart | |
| Leukemia L1210 | |
| Leukemia, Experimental | |
| Mice | |
| Sarcoma, Experimental |
Source PubMed
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 196 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36551106 | Preparation of a Highly Sensitive Electrochemical Aptasensor for Measuring Epirubicin Based on a Gold Electrode Boosted with Carbon Nano-Onions and MB. | Biosensors (Basel) | 2022 | https://conductscience.org/library/papers/36551106 | PubMed |
| 31807919 | Cerium-doped flower-shaped ZnO nano-crystallites as a sensing component for simultaneous electrochemical determination of epirubicin and methotrexate. | Mikrochim Acta | 2019 | https://conductscience.org/library/papers/31807919 | PubMed |
| 24277182 | Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. | Pharm Res | 1984 | https://conductscience.org/library/papers/24277182 | PubMed |
| 16107896 | Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. | Leukemia | 2005 | https://conductscience.org/library/papers/16107896 | PubMed |
| 9330607 | Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs. | Jpn J Cancer Res | 1997 | https://conductscience.org/library/papers/9330607 | PubMed |
| 8070217 | Clinical pharmacokinetics of epirubicin. | Clin Pharmacokinet | 1994 | https://conductscience.org/library/papers/8070217 | PubMed |
| 8043941 | Potential role of oral anthracyclines in older patients with cancer. | Drugs Aging | 1994 | https://conductscience.org/library/papers/8043941 | PubMed |
| 7693418 | Epirubicin. Clinical pharmacology and dose-effect relationship. | Drugs | 1993 | https://conductscience.org/library/papers/7693418 | PubMed |
| 6946877 | Evaluation of new anthracycline analogs with the human tumor stem cell assay. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/6946877 | PubMed |
| 6940195 | Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. | Proc Natl Acad Sci U S A | 1981 | https://conductscience.org/library/papers/6940195 | PubMed |
| 6831630 | Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6831630 | PubMed |
| 6678877 | Phase I trial with 4'-deoxydoxorubicin (esorubicin). | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678877 | PubMed |
| 6595240 | Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. | Invest New Drugs | 1984 | https://conductscience.org/library/papers/6595240 | PubMed |
| 6590530 | Phase I study of 4-demethoxydaunorubicin. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6590530 | PubMed |
| 6590528 | Pharmacokinetics of 4'-epi-doxorubicin in man. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6590528 | PubMed |
| 6583205 | 4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors. | J Cancer Res Clin Oncol | 1984 | https://conductscience.org/library/papers/6583205 | PubMed |
| 6579052 | Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors. | J Cancer Res Clin Oncol | 1983 | https://conductscience.org/library/papers/6579052 | PubMed |
| 6511232 | Phase II study of carminomycin in a human tumor cloning assay. | Invest New Drugs | 1984 | https://conductscience.org/library/papers/6511232 | PubMed |
| 3863718 | Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3863718 | PubMed |
| 3859341 | Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study. | Blut | 1985 | https://conductscience.org/library/papers/3859341 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/455325
GET https://conductscience.org/api/papers/v1/455325/cited_by?page=2